慢性前列腺炎诊疗进展

慢性前列腺炎 (CP)尤其非细菌性前列腺炎 (NBP)———慢性骨盆疼痛综合征 (CPPS)发病机理至今不甚明了 ,人群发病率为 2 .5 %～ 16 % ,几乎各个年龄组和种族均可发病。 2 0世纪 90年代以来 ,在国际前列腺炎协作网(IPCN)、美国国立卫生院慢性前列腺炎协作研究网 (NIH CPCRN)等国际研究机构的协调下 ,各国研究者对CP的病因、诊断、治疗等诸方面进行了较以往更大规模的广泛、深入的研究。近年来的主要成果有 :CP多因素、多步骤的发病机制、新的临床分类系统、症状评分体系 (NIH CPSI)的建立、新的诊断标准及规范化临床评估、治疗新技术的尝试等等。今后的研究重点包括分类系统的进一步完善 ,治疗方法、药物验证及筛选等方面。

Advances in the Diagnosis and Treatment of Chronic Prostatitis

So far the etiology of chronic prostatitis(CP), particularly chronic nonbacterial prostatitis(NBP) or chronic pelvic pain syndrome (CPPS), remains to be elucidated. According to recent epidemiologic data, the prevalence of CP ranged from 2.5 % to 16% of the world population, affecting men of all ages and all ethnic origins. Since 1990s researchers of many countries have carried out larger scaled, deeper and more extensive studies than ever before on the etiology, diagnosis and treatment of the disease, with the sponsorship and coordination of such international institutions as the International Prostatitis Collaborative Network(IPCN), the Chronic Prostatitis Collaborative Research Network of the National Institute of Health (NIH CPCRN) and so on. The main achievements of recent years include: the etiology of CP/CPPS being a complicated multi step and multi factor course, the establishment of the new clinical classification system, the introduction of the National Institute of Health chronic prostatitis symptom index, the new criteria of diagnosis and standardized clinical evaluation, the primary explorations of new treatment methods and medicines, etc. Further investigations suggested are the optimization of clinical classification, the screening and verification of treatment methods and medicines for CP/CPPS, etc.